Bristol Myers to Acquire Karuna, a Leading Schizophrenia Drug Manufacturer, in $14 Billion Deal In a significant move within the...
Lilly Collaborates with Fauna Bio to Explore Novel Obesity Drugs Obesity has become a global epidemic, affecting millions of people...
Lilly Collaborates with Fauna Bio to Explore New Obesity Drugs Obesity has become a global epidemic, affecting millions of people...
Arrowhead Pharmaceuticals, a biopharmaceutical company specializing in the development of RNA interference (RNAi) therapeutics, has recently announced that it has...
Unnatural Products, a biotechnology company specializing in drug development, has recently secured $32 million in funding to further accelerate its...
Unnatural Products, a biotechnology company specializing in drug development using AI-enhanced macrocycles, has recently secured $32 million in funding. This...
Metrion Biosciences, a leading contract research organization (CRO) specializing in ion channel drug discovery and safety profiling, has recently announced...
In the fast-paced world of biotechnology, keeping an eye on emerging companies can be crucial for investors and industry professionals...
Conflict Arises Between Prime Medicine and Mukherjee’s Myeloid Therapeutics Regarding Genome-Editing Agreement In the rapidly evolving field of genome editing,...
CIRM Introduces Interim CEO in Recent Announcement The California Institute for Regenerative Medicine (CIRM) has made a recent announcement regarding...
CIRM Reveals Appointment of Interim CEO The California Institute for Regenerative Medicine (CIRM) has recently announced the appointment of Dr....
Tome, a leading biotech company, has recently announced that it has raised an impressive $213 million in funding. This significant...
European Regulators Advocate for Approval of Biogen and CRISPR Drugs In a significant development for the biotechnology industry, European regulators...
CymaBay Therapeutics, a biopharmaceutical company focused on developing innovative therapies for liver and metabolic diseases, has recently announced its submission...
Bristol Myers Squibb, a leading global biopharmaceutical company, recently announced its acquisition of SystImmune for a whopping $800 million. This...
